Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
November 1, 2006

Sapient Discovery Provides Insight on Lpath’s Cancer Drug Candidate

  • Sapient Discovery and Lpath reported the successful completion of a study to assess Lpath’s agent to treat cancer and various ocular diseases. The collaboration used Sapient Discovery's computational platform to understand the binding properties of Lpath's humanized sphingomab antibody to its target, sphingosine-1-phosphate (S1P).

    "Sapient Discovery's proprietary Genes-to-Leads technology created dynamic 3-D structural models of the binding of Sphingomab to S1P," explains Kal Ramnarayan Ph.D., president and CSO of Sapient Discovery, "This has provided valuable insights for the Lpath research team with significant efficiency and cost savings to Lpath."

    Lpath says it is the first to generate therapeutic Mabs against S1P, a bioactive lipid involved in angiogenesis and the progression of cancer.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.